ABSTRACT
This chapter discusses ethopropazine, a neuropsychotropic drug. It presents the approved indications of the drug for neuropsychological disorders, usual dosage and administration, available dosage forms, storage, and compatibility, and the mechanism of action. Information on relative contraindications, clinically significant drug interactions, adverse drug reactions, and overdosage is also provided. Sold under the trade name Parsitan®, ethopropazine pharmacotherapy is indicated for the symptomatic management of the various forms of Parkinson’s disease, including drug-induced Parkinson’s disease. The exact mechanism of the antiparkinsonian action of ethopropazine has not yet been fully determined. However, it appears to involve its anticholinergic action. Ethopropazine pharmacotherapy has commonly been associated with blurred vision, dizziness, drowsiness, dry mouth, headache, lassitude, and paresthesia. Clinical data concerning ethopropazine overdosage are not available.
